Dr. Alana Welm Appointed Chair of Oncological Sciences at University of Utah’s Spencer Fox Eccles School of Medicine

Alana Welm, PhD, has recently been appointed chair of the Department of Oncological Sciences at the Spencer Fox Eccles School of Medicine, University of Utah, marking a significant milestone in the institutional efforts to deepen the integration of basic science and clinical oncology. With immediate effect, Welm assumes a leadership role critical to advancing the department’s mission in breaking new ground in cancer biology and translational research.

As chair, Welm inherits a multifaceted mandate to sculpt a visionary roadmap aligning research excellence with academic innovation, fostering a robust ecosystem that bridges laboratory discoveries with clinical applications. Her leadership will be instrumental in steering the department’s research priorities in synergy with University of Utah Health and Huntsman Cancer Institute, ensuring that cutting-edge scientific insights translate into tangible improvements in cancer diagnoses and therapies.

Balancing administrative stewardship with scientific oversight, Welm will spearhead efforts to secure competitive federal and private funding, emphasizing peer-reviewed grants, particularly from the National Institutes of Health. She will also oversee academic programming, faculty development, and resource allocation—pillars essential for sustaining a vibrant research culture that prioritizes both fundamental and translational oncology.

Welm’s expertise is deeply rooted in elucidating the complex mechanisms underlying breast cancer metastasis—a formidable challenge in oncology where understanding cellular dissemination and colonization is pivotal to innovating treatments. Her labs have successfully transitioned foundational discoveries into clinical hypotheses, illuminating pathways that govern tumor progression and therapeutic resistance.

Notably, Welm’s research employs sophisticated molecular biology techniques, coupled with advanced in vivo models, to dissect the signaling networks and tumor microenvironment interactions that fuel metastatic spread. This integrative approach underscores a commitment to unraveling cancer’s heterogeneity and pinpointing precise molecular vulnerabilities amenable to intervention.

Describing Welm’s appointment, interim dean Sam Finlayson, MD, highlights her unique capacity to fuse visionary science with collaborative leadership. This dual capability is essential in today’s intricate biomedical landscape, where interdisciplinary teams catalyze breakthroughs, and mentorship shapes future scientific leaders. Welm exemplifies this paradigm through her record of fostering translational initiatives and securing substantial external funding.

Welm’s academic journey traces a path through rigorous training and impactful scholarship. She obtained her PhD in cell and molecular biology at Baylor College of Medicine, completing advanced postdoctoral studies at the University of California, San Francisco. Since founding her laboratory at Huntsman Cancer Institute in 2007, she has consistently expanded its role as a nexus for pioneering breast cancer metastasis research.

Her ascension to chair is lauded by Mary Beckerle, PhD, CEO of Huntsman Cancer Institute, who emphasizes Welm’s international stature and exceptional ability to catalyze interdisciplinary collaborations spanning researchers, clinicians, and patient advocates. Such coalitions are vital in translating molecular insights into clinical innovations capable of improving patient outcomes globally.

Welm’s accolades attest to her scientific impact. In 2023, she received the University of Utah Distinguished Research Award and the American Association for Cancer Research Outstanding Investigator Award for Breast Cancer Research. Additionally, her presidency of the Metastasis Research Society underscores her leadership on the international stage, facilitating research aimed at understanding and interrupting metastatic disease processes.

Articulating her vision, Welm expresses a profound commitment to advancing a culture of scientific excellence and innovative collaboration within the department. She aims to harness the department’s strengths to train the next generation of cancer researchers and clinicians, positioning the University of Utah and Huntsman Cancer Institute at the forefront of emerging cancer therapies and precision medicine.

Welm’s leadership comes at a time when interdisciplinary and translational research is increasingly recognized as essential in oncology. By guiding the department’s academic and operational frameworks, she is poised to elevate its national profile and impact, ensuring that discoveries in molecular oncology swiftly inform clinical trials and patient care strategies.

Her predecessor, Brad Cairns, PhD, is credited with laying a robust foundation through recruiting high-impact investigators and fostering environments conducive to translational breakthroughs. Though stepping down as chair, Cairns remains a vital figure as a Howard Hughes Medical Investigator, continuing to influence cancer research and mentorship at the University of Utah and Huntsman Cancer Institute.

The Huntsman Cancer Institute itself, designated as a National Cancer Institute Comprehensive Cancer Center, serves a vast multi-state region with cutting-edge research and clinical trials focused on a cancer-free future. Its integration with University of Utah Health’s academic and clinical resources creates a synergistic hub for innovative cancer care and discovery.

With over 300 active clinical trials and more than 250 research teams, Huntsman Cancer Institute exemplifies the translational research model Welm aims to amplify. Its rich history of genetic discoveries and tailored cancer treatments provides a fertile context for Welm’s leadership to further scientific exploration into the molecular determinants of cancer metastasis and therapeutic resistance.

Located within a comprehensive academic health system, University of Utah Health boasts extensive biomedical research infrastructure and healthcare delivery networks, encompassing multiple hospitals and clinics. This environment offers Welm a powerful platform to align research priorities with patient-centered care, accelerating the bench-to-bedside trajectory of oncological innovations.

In sum, Alana Welm’s appointment as chair of the Department of Oncological Sciences heralds a transformative era for cancer research at the University of Utah. Her scientific acumen, strategic vision, and commitment to mentorship promise to advance molecular oncology, bolster translational research, and ultimately impact cancer treatment paradigms on a national and international scale.

—